학술논문

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
Document Type
Article
Source
In Clinical Lung Cancer November 2020 21(6):498-508
Subject
Language
ISSN
1525-7304